Results 191 to 200 of about 13,195 (282)

Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer. [PDF]

J Med Chem, 2023
Sun N, Kabir M, Lee Y, Xie L, Hu X, Velez J, Chen X, Kaniskan HÜ, Jin J.   +8 more
europepmc   +1 more source

Oncofetal Biology: From Fundamental Mechanisms to Emerging Therapeutic Opportunities

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Oncofetal biology provides a transformative framework for understanding cancer initiation, progression, and therapeutic intervention. This review synthesizes the core molecular mechanisms connecting embryonic development and tumorigenesis from a multidisciplinary standpoint and outlines future research trajectories and clinical applications, and we aim
Yang Liu, Kaifeng Niu, Qingran Kong, Shaorong Gao   +3 more
wiley   +1 more source

Fenofibrate potentiates the therapeutic efficacy of EZH2 inhibitors on melanoma via TRIM21‐ and OTUD4‐mediated EZH2 ubiquitination

British Journal of Pharmacology, Volume 183, Issue 11, Page 2675-2694, June 2026.
Background and Purpose EZH2 (enhancer of zeste homologue 2) inhibitors are an emerging class of drugs that target epigenetic regulation. However, their efficacy in solid tumours has been limited, partly due to drug‐induced upregulation of fatty acid synthesis.
Rui Cheng, Yuanjun Tang, Xuedi Cao, Xiaotong Yu, Zhanya Huang, Yunyun Guo, Renjing Jin, Yan Wang, Yang Liu, Lixiang Xue, Yuqing Wang   +10 more
wiley   +1 more source

The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants. [PDF]

Front Pharmacol, 2022
Ye W, Wu X, Wang X, Wei X, Tang Y, Ouyang X, Gong Y.   +6 more
europepmc   +1 more source

Common Hematologic Emergencies—Acute Promyelocytic Leukemia and Microangiopathic Hemolytic Anemias—A Pivotal Role of Clinical Laboratory

International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 521-530, June 2026.
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova, Nicolas Ulrich Edgar, Anton V. Rets   +2 more
wiley   +1 more source

Telomerase reverse transcriptase degradation via a rationally designed covalent proteolysis targeting chimera. [PDF]

Bioorg Med Chem Lett
Frost GB, Liu Y, Kron SJ, Scheidt KA.
europepmc   +1 more source

Cell Morphological Profiling Enables High-Throughput Screening for PROteolysis TArgeting Chimera (PROTAC) Phenotypic Signature. [PDF]

ACS Chem Biol, 2022
Trapotsi MA, Mouchet E, Williams G, Monteverde T, Juhani K, Turkki R, Miljković F, Martinsson A, Mervin L, Pryde KR, Müllers E, Barrett I, Engkvist O, Bender A, Moreau K.   +14 more
europepmc   +1 more source

Hypoxic and Fe‐Responses are Regulated by the ERFVII Factors and the PCO Branch of the N‐Degron Pathway According to Iron Availability

Plant, Cell &Environment, Volume 49, Issue 6, Page 3363-3380, June 2026.
ABSTRACT In plants, iron homeostasis and oxygen metabolism are strictly related, indeed several Fe‐requiring enzymes catalyze reactions that also involve O2 as a reagent, product, entry or end point of the pathway. Oxygen sensing itself relies on the Fe‐dependent enzymes Plant cysteine oxidases.
Yuri Telara, Moez Maghrebi, Mikel Lavilla‐Puerta, Noemi La Monaca, Giulia Ambrogini, Alessio Sbrana, Sara Delucchi, Pierdomenico Perata, Gianpiero Vigani, Beatrice Giuntoli   +9 more
wiley   +1 more source

DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1-CDK4/6 Complex Protein Degradation. [PDF]

J Am Chem Soc
Zheng R, Prasad A, Satyabola D, Xu Y, Roy S, Yan Y, Šulc P, Yan H.   +7 more
europepmc   +1 more source

A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth. [PDF]

J Hematol Oncol, 2022
Li X, Yao Y, Wu F, Song Y.
europepmc   +1 more source